Targeting HER2: Recent developments and future directions for breast cancer patients

Seminars in Oncology

Volumn 28, Issue 6 SUPPL. 18, 2001, Pages 21-29

  Shao Chun, Wang ^a   Lisha, Zhang ^a   Hortobagyi, Gabriel N ^a   Mien Chie, Hung ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; E1A PROTEIN; EMODIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GENE PRODUCT; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; PACLITAXEL; POLVOMAVIRUS ENHANCER ACTIVATOR 3; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG SENSITIZATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0035680513     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90105-8     Document Type: Review

References (110)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
3. Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. erbB-4
6. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
7. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
8. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
9. The erbB-3 gene product is a receptor for heregulin
10. Hyperexpression of mitogen-activated protein kinase in human breast cancer
11. HER-2/neu signal transduction in human breast and ovarian cancer
12. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: Synergistic transcription factor interactions are targets for cancer therapy
13. Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments. Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site
14. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation
15. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
16. Regulation of cell death protease caspase-9 by phosphorylation
17. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway
18. neu: A relationship between disruption of this regulation and transformation
19. neu
20. Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor
21. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in NJH 3T3 cells
22. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
23. Amplification of the protoneu gene facilitates oncogenic -activation by a single point mutation
24. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
25. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
26. Prognostic importance of c-erbB-2 expression in breast cancer
27. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30 year follow-up
28. Overexpression of HER-2/neu associated with poor survival in advanced epithelial epithetial ovarian cancer
29. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
30. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
31. neu) in human non-small cell carcinomas of the lung
32. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer
33. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
34. Amplification, overexpression, and rearrangement of the c-erbB-2 proto-oncogene in primary-human stomach carcinomas
35. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
36. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
37. c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
38. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 EIA gene products
39. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
40. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but noT with ras gene mutations
41. neu in HER-2/neu transfected human lung cancer cells
42. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
43. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
44. Heregulin beta 1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase
45. From HER-2/neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
46. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
47. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
48. mdr renders breast cancer cells highly resistant to taxol
49. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
50. cdc2 kinase
51. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
52. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
53. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel
54. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin
55. neu
56. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
57. Mechanisms of deregulated HER2/neu expression in breast cancer cell lines
58. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma
59. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumor cell lines
60. Cloning and characterization of the mouse neu promoter
61. Regulation of HER-2/neu gene expression
62. Identification and characterization of a novel enhancer for the rat neu promoter
63. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
64. The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu
65. Repressed expression of the HER-2/neu/c-erbB-2 proto-oncogene by the adenovirus EIA gene products
66. Adenovirus type 5 EIA products acts as transformation suppressors of the neu oncogene
67. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer
68. Transcriptional repression of the neu proto-oncogene by the adenovirus 5 EIA gene products
69. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells
70. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
71. Differential transformation of primary human embryo retinal cells by adenovirus EIA regions and combination of EIA + ras
72. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
73. Complete transformation by adenovirus 2 requires both EIA proteins
74. Re-expression of neu-encoded oncoprotein counteracts the tumor-suppressing activity of EIA
75. Adenovirus EIA-mediated negative control of genes activated during F 9 differentiation
76. Adenovirus EIA represses protease gene expression and inhibits metastasis of human tumor cells
77. Liposome-mediated in vivo EIA gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu
78. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by EIA
79. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene
80. Potentiation of cationic liposome-mediated gene delivery by polycations
81. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
82. HER-2/neu-targeting cancer therapy via adenovirus-mediated EIA delivery in an animal model
83. The tumor suppression activity of EIA in HER-2/neu-overexpressing breast cancer
84. The EIA gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells
85. Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with the adenovirus-5 EIA gene
86. Antioncogenic effect of adenovirus EIA in human tumor cells
87. Adenovirus EIA-mediated tumor suppression by a c-erbB2/neu-independent mechanism
88. Adenovirus 5 EIA-mediated tumor suppression associated with EIA-mediated apoptosis in vivo
89. Axl-Gas6 interaction counteracts EIA-mediated cell growth suppression and proapoptotic activity
90. The adenovirus EIA proteins induce apoptosis, which is inhibited by the EIB 19-kDa and Bcl-2 proteins
91. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 EIA and accompanies apoptosis
92. Inhibition of nuclear factor-kappa B activity is involved in EIA-mediated sensitization of radiation-induced apoptosis
93. EIA sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of 1κB kinases and nuclear factor κB activities
94. p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: Suppression by E1B 19K and Bcl-2 proteins
95. p53-dependent apoptosis suppresses tumor growth and progression in vivo
96. Wild-type p53 mediates apoptosis by EIA, which is inhibited by EIB
97. Adenovirus EIA proteins induce apoptosis by both p53-dependent and p53-independent mechanisms
98. HER-2/neu-targeting via adenovirus-mediated EIA delivery in an animal model
99. Safety studies of the intraperitoneal injection of EIA-liposome complex in mice
100. Safety study and characterization of EIA-liposome complex gene-delivery protocol in an ovarian cancer model
101. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells
102. Differentiation-stimulated activity binds an ETS-like, essential regulatory element in the human promyelocytic defensin-1 promoter
103. A role for the ETS domain transcription factor PEA3 in myogenic differentiation
104. ERM, a PEA3 subfamily of Ets transcription factors, can cooperate with c-Jun
105. Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins
106. The ETS-domain: A new DNA-binding motif that recognizes a purine-rich core DNA sequence
107. The ets multigene family is conserved throughout the Metazoa
108. Evolution of the ets gene family
109. A single ets-related transcription factor, EIAF, confers invasive phenotype on human cancer cells
110. Expression of the PEA3 group of EST-related transcription factors in human breast cancer cells